Yinjia (Shanghai) Biomedical Technology
Protein R&D for biomedical and life sciences
About Yinjia (Shanghai) Biomedical Technology
Yinjia (Shanghai) Biomedical Technology Co., Ltd. is a protein technology research and development company established in November 2020. The company's founder is Dr. Wu Yifei, who serves as Chairman and CEO.
Yinjia focuses on the application of proteins in biomedicine and other life science fields. It has developed a protein R&D platform that utilizes computer simulation, artificial intelligence, and Cell-Free Protein Synthesis (CFPS) technologies. The company produces high-quality protein-based biomaterials and reagents for applications such as early cancer diagnosis, new drug development, and personalized medication guidance. Its product portfolio includes nearly 200 high-end protein raw materials and quality control testing reagents for therapeutic biologics. These products cover frontier fields like cell and gene therapy (CGT), mRNA and circRNA vaccines, molecular diagnostics, and new anti-tumor drugs. Specific offerings mentioned include Vaccinia Capping Enzyme, 2'-O-methyltransferase, and T7 RNA Polymerase V2, which are produced using E. coli expression systems.
The company operates on a B2B model, providing its products to pharmaceutical companies, innovative drug developers, and diagnostic companies to support their research and development efforts. Yinjia has established laboratories and GMP pilot production platforms in Shanghai, Suzhou, and Beijing. Strategic partnerships are a key part of its growth strategy. In 2021, Yinjia signed a deal with US biotech firm IsoPlexis to advance a proteomics data analysis platform for monitoring therapeutic effects on tumor patients. In 2023, it partnered with Porton Advanced Solutions to develop core protein raw materials and quality control reagents for the CGT sector.
Yinjia has successfully completed multiple funding rounds. It secured tens of millions of yuan in a seed round in January 2021 from investors including CDH Venture and Growth Capital Fund. This was followed by a Pre-A round in July 2021, led by Gaorong Capital, which also raised tens of millions of yuan. In December 2022, the company completed a Series A round of over CNY 100 million (approximately $14M), led by CMB International. Other notable investors across its funding stages include InnoPinnacle and Shanghai Furong Investment. These funds have been allocated towards talent recruitment, expanding production capacity, enhancing its protein optimization platform, and advancing global collaborations.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 19.0/100
- Industry
- Marketing
- Sector
- Hard Tech
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2023 | $14M | $55M | InnoPinnacle Fund · CMB International | ↗ |
Growth signals
Latest recorded traffic for Yinjia (Shanghai) Biomedical Technology is 230 monthly website visits, up 76.9% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Yinjia (Shanghai) Biomedical Technology in its local ecosystem
The Yinjia (Shanghai) Biomedical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- CICMB International
InnoPinnacle Fund
Other known investors3 additional known investors
CDH Investments
Gaorong Ventures- SIShanghai Furong Investment
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Yinjia (Shanghai) Biomedical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Yinjia (Shanghai) Biomedical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








